CLVS is a stock of interest due to the large impact the company has on the market. Here at Wall Street Facts we only cover the best stocks so make sure you check out our other articles. Today we will be diving deep into all of the essential information you need to know about CLVS. We will be studying the movement so you can make the best decision as an investor. The stock has moved $0.6 from yesterday’s closing price of $5.71. The high for today is $7.24 and the low for today is $6.22. Let’s learn more about the company and then get into the forecast.
Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of cancer treatments. Its marketed product Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is offered for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer; and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.
As an investor, you can get an idea of where the stock is trending by the forecast. In this case, CLVS is projected to have a price of $8.7975 in one year which is a 139.421553090333% change. They have a strong market cap of $569.8792 and a very bright future ahead of them. Make sure to subscribe to our newsletter to never miss an update!